Navigation Links
deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
Date:10/12/2011

REYKJAVIK, Iceland, October 12, 2011 /PRNewswire/ --

deCODE genetics today announced that it has entered into a research collaboration with Pfizer Inc., the objective of which is to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus Erythematosis by utilizing deCODE's expertise in gene discovery.

deCODE's discovery capabilities combine its extensive population and genetic resources, including DNA samples and medical data, complete genealogical information, next generation sequencing technology, and deCODE's proprietary bioinformatics and statistical capabilities. Over the next 18 months, deCODE and Pfizer will work together to analyse the genomes of patients to search for sequence variants that would be useful for understanding drug targets and discovering novel drug targets, that may ultimately lead to tools for patient stratification and companion diagnostics.

"This agreement is a part of deCODE's ongoing strategy to unleash the value of human genetics," said Kari Stefansson, founder and CEO of deCODE, "our research platform allows us to understand the genetic basis of disease and modifiers of clinical phenotypes in actual patient populations; by doing so, we can rapidly move from targets to patient stratification and from there to companion diagnostics."

The research collaboration will utilize the expertise and capabilities of both deCODE and Pfizer: deCODE's comprehensive population genetics resources and analytical expertise and Pfizer's dedication to the application of genomic analysis to the discovery and development of drugs.

About deCODE

Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.

In order to most rapidly realize the value of genetics for human health, deCODE is currently partnering with life sciences companies to accelerate their target discovery, validation, and prioritization efforts, yielding improved patient stratification for clinical trials and essential companion diagnostics. In addition, through its CLIA- and CAP-certified laboratory, deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases.  deCODE also licenses its tests, intellectual property, and analytical tools to partner organizations.  deCODE's corporate information can be found at http://www.decode.com with information about our genetic testing services at http://www.decodehealth.com and http://www.decodeme.com

Contact:
Gisli Arnason
+354-570-1825
gisli.arnason@decode.is


'/>"/>

SOURCE deCODE genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels
2. deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers
3. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
4. The New deCODE Map of the Human Genome
5. deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma
6. ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test
7. deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases
8. deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk
9. deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal
10. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
11. Amaizing: Corn genome decoded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Today, BioPharma ... has announced the addition of 5 new courses to its prospectus. These include ... Regulation 21 CFR Part 11 on Electronic Records and Electronic Signatures (Part 11 ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... has appointed Vishwas Paralkar to the role of chief scientific officer. In this ... will report to Cybrexa’s president and CEO, Per Hellsund. , “I was impressed ...
(Date:9/20/2017)... Worth, Texas (PRWEB) , ... September 20, 2017 , ... ... stem cell therapy succeeded after standard medicine failed. Many of these people had lost ... Progress, Not Regression Free Download (pdf) , “Neil takes ...
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author and an ... “Grit” author Angela Duckworth and her team at Character Lab have joined Philadelphia’s ... international law firm with decades of experience supporting high-growth companies in the technology ...
Breaking Biology Technology:
(Date:7/20/2017)... -- Delta (NYSE: DAL ) customers now can use fingerprints ... Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National ... Delta,s biometric boarding pass experience that launched ... into the boarding process to allow eligible Delta SkyMiles Members who are ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):